Searchable abstracts of presentations at key conferences in endocrinology

ea0022p405 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Cinacalcet hydrochloride effectively controlled primary hyperparathyroidism in patients unresponsive to bisphosphonates

Faggiano Antongiulio , Somma Carolina Di , Milone Francesco , Ramundo Valeria , Rota Francesca , Vuolo Laura , Guerra Ermelinda , Colao Annamaria

Context: Until now the role of medical therapy in patients with primary hyperparathyroidism (PHP) was mainly based on the use of bisphosphonates. Recently, cinacalcet hydrochloride was reported to be effective in control hypercalcemia in PHP. The aim of this study was to evaluate the efficacy of cinacalcet in PHP patients who were not effectively controlled with alendronate.Patients and methods: Fourteen PHP patients (mean age 64.1±2.6) were include...

ea0063p36 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Vitamin D deficiency is a predictor marker of tumor aggressiveness in sporadic and MEN1-related well-differentiated, low-grade GEP-NET

Altieri Barbara , Barrea Luigi , Modica Roberta , Circelli Luisa , Bottiglieri Filomena , Cicco Federica De , Savarese Giovanni , Somma Carolina Di , Colao Annamaria , Savastano Silvia , Faggiano Antongiulio

Background: Vitamin D has several ‘noncalcemic’ implications, including effects on cell signaling and differentiation. Patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET) have an increased risk of vitamin D deficiency, due to the tumor itself, systemic therapies and abdominal surgery. However, data regarding vitamin D status are limited. Aim of this study was to evaluate 25-hydroxy-vitamin-D (25(OH)D) levels in GEP-NET patients and correlated them ...